Kyverna Therapeutics has begun a rolling submission to the FDA for miv-cel, after the agency requested additional natural history analysis. The company said the added work is intended to support review of what it characterizes as the first autoimmune CAR-T program to reach the market. The update places emphasis on the FDA’s focus on evidence quality beyond standard trial datasets, particularly for autoimmune indications where historical clinical context may affect benefit-risk framing. Rolling submissions allow the agency and applicant to review modules as they are prepared rather than waiting for a complete package. For developers of cell therapies, the move highlights how “data readiness” requirements can extend natural-history and retrospective evidence collection even after key clinical milestones. It also illustrates the continuing importance of regulatory engagement during late-stage development for cell and gene therapy candidates. Investors and competitors will watch whether the expanded natural-history work delays timelines or instead improves alignment on endpoints and comparators.